Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02617810 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02617810 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 18 participants.
The verdict
NCT02617810, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate effect of multiple-dose administration of JNJ-42847922 on the single-dose pharmacokinetics of oral midazolam and single-dose pharmacokinetics and pharmacodynamics of (R)- and (S)-warfarin after oral administration of racemic warfarin.
Interventions
- DRUG Midazolam
- DRUG Warfarin
- DRUG JNJ-42847922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02617810
The ClinicalTrials.gov registry entry for NCT02617810 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Midazolam is the first listed.
NCT02617810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02617810 about?
NCT02617810 is a clinical study titled "A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants". The purpose of this study is to evaluate effect of multiple-dose administration of JNJ-42847922 on the single-dose pharmacokinetics of oral midazolam and single-dose pharmacokinetics and pharmacodynamics of (R)- and (S)-warfarin after oral administration of racemic warfarin.
What is the current status of trial NCT02617810?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2015-11. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02617810?
The interventions under investigation include: Midazolam (DRUG), Warfarin (DRUG), JNJ-42847922 (DRUG).
Who is sponsoring clinical trial NCT02617810?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.